Skin
SNAP-8
Octapeptide · SNAP-25 N-terminus analogue · 8 amino acids
FDA · NOT REVIEWED (COSMETIC)
Half-life
~3 hours
Short
minsdays
Route
Topical cream/serum
Evidence
Preclinical only
Risk
Standard
Overview
Known for
Mechanism
Key facts
Format
Lyophilized powder
Mechanism targets
Classification
Secondary
Supply & nature
ExogenousExogenous
FDA category
Not reviewed (cosmetic)
Evidence & standing
Evidence base
Preclinical only
Risk level
Standard
Best studies
5 references
Dosage & protocol
Typical dose
50-100mcg
Research range
10–50 µg
Cycle
Daily topical application
Onset
21 days first effects
Full effect
70 days
Half-life
~2-4h (topical)
~Hours (topical compound, not injectable)
Protocol
Time to effects
Recommended vial
Reference figures only
Dosing reflects published laboratory protocols and is not guidance for use in any living subject.
Safety
Reversibility
Fully Reversible
Side effects
Interactions
Handle with research caution
Storage & handling
Lyophilised
12–24 months
Room temp
Reconstituted
4–6 weeks
2–8°C